Riluzole topical - Biofrontera AG

Drug Profile

Riluzole topical - Biofrontera AG

Alternative Names: BF-37

Latest Information Update: 29 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biofrontera AG
  • Class Benzothiazoles; Neuroprotectants; Small molecules; Thiazoles
  • Mechanism of Action T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Atopic dermatitis; Psoriasis

Most Recent Events

  • 07 May 2007 Biofrontera initiates enrolment in a phase II trial for Atopic dermatitis in Germany
  • 15 Mar 2007 Phase-II development is ongoing
  • 08 Sep 2005 Biofrontera AG acquires topical riluzole from Switch Biotech AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top